Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Alzheimer's Disease Research - Current Award

Dr. Randall Bateman

Randall Bateman, M.D.

Washington University
St. Louis, MO

Title: Human CNS-Apolipoprotein E Isoform Production and Clearance
Non-Technical Title: Metabolism of the protein (ApoE) that increases risk of Alzheimer's Disease in humans.

Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
Award Amount: $150,000


Summary:

Although te ApoE is the strongest genetic risk factor for Alzheimer's disease, relatively little is known about the how ApoE contributes to that risk. This study seeks to characterize basic biological differences between three different ApoE alleles.

Details:

Alzheimer's disease is the most common cause of dementia, and the most feared disease of Americans over the age of 65. ApoE is the strongest genetic risk factor for Alzheimer's disease, and is a potential target for disease-modifying therapies. The ApoE4 allele, which occurs in 15 percent of the population, increases one's risk of developing Alzheimer's Disease by 3-fold, while two copies of ApoE4 increase this risk by 12-fold. Whereas the E2 allele, occurring in 7 percent of the population, decreases one's risk of developing Alzeimer's disease. The hypothesis being tested is the three ApoE isoforms (E2, E3 and E4) have different rates of synthesis and clearance. We will measure the metabolism of ApoE from the cerebrospinal fluid of young, non-demented participants. This study will provide an important link regarding how ApoE4 may be involved in the pathophysiology of Alzheimer's disease, and may lead to improved therapeutics, which target the major genetic risk factor of Alzheimer's disease, ApoE.